Sequential cyclic combined hormonal therapy for metastatic breast cancer

Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer.

BACKGROUND Recent years have brought significant progress to the development of hormonal therapies for the treatment of breast cancer. Several new agents have been approved for the treatment of breast cancer in the metastatic setting, among which is the new non-steroidal aromatase inhibitor, anastrozole, introduced for clinical use in Israel in March 1997. OBJECTIVE To evaluate the response r...

Hormonal and Chemotherapeutic Systemic Therapy for Metastatic Prostate Cancer.

BACKGROUND: Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer death in men in the United States. It is estimated that over 300,000 men will have been diagnosed with prostate cancer in 1996, and more than 40,000 will have died of this disease. METHODS: The authors combined their experience with a review of the literature on management of this disease ...

HER2-directed therapy for metastatic breast cancer.

Human epidermal growth factor receptor 2 (HER2) overexpression drives the biology of 20% of breast cancers, and predicts a poor prognosis for patients. HER2-targeted therapies significantly improve outcomes for HER2-positive patients with both early and metastatic breast cancer. Currently three HER2-targeted agents, trastuzumab (Herceptin), lapatinib (Tykerb), and pertuzumab (Perjeta), are avai...

Breast Cancer Postanthracycline Therapy for Metastatic Disease

Antiangiogenic Therapy for Metastatic Breast Cancer

Introduction Breast cancer is the most commonly diagnosed cancer in women and is the second leading cause of cancer-related mortality, after lung cancer.1 The overall incidence of breast cancer was increasing until recently, but mortality has declined since 1990, presumably due to earlier detection and better treatments.1 Despite great advances in the current therapeutic options for the treatme...